Biopsy News and Research RSS Feed - Biopsy News and Research

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.
Nanoparticles of ultrapure silicon act as luminescent markers in early diagnosis of cancer

Nanoparticles of ultrapure silicon act as luminescent markers in early diagnosis of cancer

The group of Russian and French researchers, with the participation of scientists from the Lomonosov Moscow State University, has succeeded to synthesize nanoparticles of ultrapure silicon, which exhibited the property of efficient photoluminescence, i.e., secondary light emission after photoexcitation. [More]
Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research. [More]
Clinical study shows sitagliptin drug not effective in treating NAFLD

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. [More]
Vessel-sparing radiation, better understanding of prostate anatomy can improve quality of life

Vessel-sparing radiation, better understanding of prostate anatomy can improve quality of life

Remember the game Operation? You need to carefully remove the body part without nicking the sides or the buzzer will sound. [More]
New IsoPSA test identifies molecular structural changes in protein biomarkers to detect prostate cancer

New IsoPSA test identifies molecular structural changes in protein biomarkers to detect prostate cancer

A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting. [More]
Celiac disease more common among Americans with Punjabi ancestry, study shows

Celiac disease more common among Americans with Punjabi ancestry, study shows

About 1.8 million Americans have celiac disease, an immune-based condition brought on by the consumption of gluten in genetically susceptible patients. Among patients diagnosed with celiac disease by small intestinal biopsy in the U.S., those from the Punjab region of India have the highest rates of disease, according to new research published in Clinical Gastroenterology and Hepatology,1 the official clinical practice journal of the American Gastroenterological Association. [More]
Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Researchers report in the journal Cancer Cell an experimental therapy that in laboratory tests on human cells and mouse models stops aggressive, treatment-resistant and deadly brain cancers called glioblastoma and high-grade gliomas. [More]
Medicare policy puts low-income Americans at increased risk for colorectal cancer

Medicare policy puts low-income Americans at increased risk for colorectal cancer

Colorectal cancer is the second highest cause of cancer death in the United States, expected to claim the lives of an estimated 49,190 people in 2016. The Affordable Care Act aimed to increase access to CRC screening by not holding patients responsible for all costs of the procedure, yet current Medicare insurance beneficiaries lacking supplemental insurance may not be able to afford colon cancer screening and treatment. [More]
Teledermatology improves patients' access to dermatologists

Teledermatology improves patients' access to dermatologists

Teledermatology significantly improved access to specialized skin care for a group of patients that traditionally has limited options, according to an independent study led by researchers at the RAND Corporation and Harvard Medical School's Department of Health. The findings appear in a JAMA Dermatology article published online May 4. [More]
Barrow research focuses on use of new technology for imaging brain tumors

Barrow research focuses on use of new technology for imaging brain tumors

Scientists at Barrow Neurological Institute have recently made discoveries about use of a new technology for imaging brain tumors in the operating room -- a finding that could have important implications for identifying and locating invading cells at the edge of a brain tumor. [More]
Liposuction to manage lymphedema? An interview with Professor John Boyages

Liposuction to manage lymphedema? An interview with Professor John Boyages

Lymphedema is persistent swelling of the arm and/or hand following biopsy or treatment of the axillary lymph nodes for patients with breast cancer. It is due to excess accumulation of protein‐rich fluid in body tissues. [More]
Combination of two diagnostic tests can decrease chance of missing tumors by sevenfold

Combination of two diagnostic tests can decrease chance of missing tumors by sevenfold

Cytopathology researchers at Houston Methodist Hospital recently found that combining two diagnostic tests, Pap and high-risk human papillomavirus (hrHPV), dramatically decreased the chance of missing tumors and high-grade lesions by sevenfold. [More]
First-ever ACR-led imaging boot camp training for breast radiologists to be held in Jeddah

First-ever ACR-led imaging boot camp training for breast radiologists to be held in Jeddah

The American College of Radiology is partnering with GE Healthcare and King Faisal Specialist Hospital & Research Center to bring the first-ever ACR-led imaging boot camp training for breast radiologists to the Middle East. The three-day Breast Imaging Boot Camp to be held May 23-25 in Jeddah will provide up to 40 practicing radiologists in Saudi Arabia and the Middle East with intensive hands-on experience in mammography and breast ultrasonography. [More]
New research reveals sliding ability of cancer cells that helps in tumor spread

New research reveals sliding ability of cancer cells that helps in tumor spread

Metas­tasis. The very word evokes fear. Defined as the spread of cancer cells from one part of the body to another, metastasis is the cause of approximately 90 percent of deaths among cancer patients. How does metastasis come about? And can we stop it?
New research from a team led by Northeastern's Anand Asthagiri, associate professor of bioengineering and chemical engineering, helps to answer those questions. It provides an astonishing look at the biophysical properties that permit breast cancer cells to "slide" by obsta­les and travel out of their primary tumor toward a blood vessel that will carry them to a new site. [More]
Protea signs license agreement with Yale to develop new technology for detecting malignant melanoma

Protea signs license agreement with Yale to develop new technology for detecting malignant melanoma

Protea Biosciences Group, Inc. announced today that it had entered into an exclusive license agreement with Yale University for new technology to improve the differential diagnosis of malignant melanoma. [More]
Hormonal contraception may increase susceptibility of women to genital infection

Hormonal contraception may increase susceptibility of women to genital infection

Women account for approximately half of all individuals living with HIV worldwide, and researchers wanted to identify the risk factors that increase susceptibility of women to genital infection. [More]
Experts discuss recent controversies related to breast cancer screening recommendations

Experts discuss recent controversies related to breast cancer screening recommendations

In 2015, American Cancer Society caused a stir in the oncology community—and among women in general—with the updated recommendation that women of average risk for breast cancer should commence annual mammography at age 45. [More]
Small fibre neuropathy defies 'dying-back' nerve process

Small fibre neuropathy defies 'dying-back' nerve process

Neuronal degradation in patients with small fibre neuropathy is not dependent on nerve fibre length, study findings suggest. [More]
Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies. [More]
First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab. [More]
Advertisement
Advertisement